{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:26:54Z","timestamp":1777487214874,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-023-01169-x","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T17:03:03Z","timestamp":1704819783000},"page":"310-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Successful Burosumab Treatment in an Adult Patient with X-Linked Hypophosphatemia and Chronic Kidney Disease Stage 3b"],"prefix":"10.1007","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-3733","authenticated-orcid":false,"given":"Arthur","family":"Michon-Colin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Bouderlique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Pri\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Maruani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Nevoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Briot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Courbebaisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"1169_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res Off J Am Soc Bone Miner Res 19:429\u2013435. https:\/\/doi.org\/10.1359\/JBMR.0301264","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"1169_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1615\/critreveukargeneexpr.v22.i1.50","volume":"22","author":"PSN Rowe","year":"2012","unstructured":"Rowe PSN (2012) Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 22:61\u201386. https:\/\/doi.org\/10.1615\/critreveukargeneexpr.v22.i1.50","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"1169_CR3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res Off J Am Soc Bone Miner Res 26:1381\u20131388. https:\/\/doi.org\/10.1002\/jbmr.340","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"7","key":"1169_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15(7):435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"key":"1169_CR5","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, H\u00f6gler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen C-Y, Skrinar A, San Martin J, Portale AA (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet Lond Engl 393:2416\u20132427. https:\/\/doi.org\/10.1016\/S0140-6736(19)30654-3","journal-title":"Lancet Lond Engl"},{"key":"1169_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen C-Y, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO, AXLES 1 Investigators (2018) A Randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with x-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res Off J Am Soc Bone Miner Res 33:1383\u20131393. https:\/\/doi.org\/10.1002\/jbmr.3475","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"1169_CR7","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1172\/JCI61405","volume":"122","author":"V Shalhoub","year":"2012","unstructured":"Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai M-M, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG (2012) FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 122:2543\u20132553. https:\/\/doi.org\/10.1172\/JCI61405","journal-title":"J Clin Invest"},{"key":"1169_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031260","volume":"8","author":"M Courbebaisse","year":"2018","unstructured":"Courbebaisse M, Lanske B (2018) Biology of fibroblast growth factor 23: from physiology to pathology. Cold Spring Harb Perspect Med 8:a031260. https:\/\/doi.org\/10.1101\/cshperspect.a031260","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1169_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","volume":"58","author":"O M\u00e4kitie","year":"2003","unstructured":"M\u00e4kitie O, Kooh SW, Sochett E (2003) Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol (Oxf) 58:163\u2013168. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01685.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1169_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15:435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"key":"1169_CR11","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00467-020-04906-8","volume":"36","author":"M Giralt","year":"2021","unstructured":"Giralt M, Chocron S, Ferrer R, Ariceta G (2021) Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia. Pediatr Nephrol Berl Ger 36:1025\u20131028. https:\/\/doi.org\/10.1007\/s00467-020-04906-8","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"1169_CR12","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1515\/cclm-2020-0460","volume":"58","author":"M-L Piketty","year":"2020","unstructured":"Piketty M-L, Brabant S, Souberbielle J-C, Maruani G, Audrain C, Rothenbuhler A, Pri\u00e9 D, Linglart A (2020) FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference. Clin Chem Lab Med 58:e267\u2013e269. https:\/\/doi.org\/10.1515\/cclm-2020-0460","journal-title":"Clin Chem Lab Med"},{"key":"1169_CR13","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu M-C, Sloan A, Isakova T, Guti\u00e9rrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393\u20134408. https:\/\/doi.org\/10.1172\/JCI46122","journal-title":"J Clin Invest"},{"key":"1169_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4274\/jcrpe.galenos.2021.2020.0287","volume":"14","author":"A Castellano-Martinez","year":"2022","unstructured":"Castellano-Martinez A, Acu\u00f1as-Soto S, Roldan-Cano V, Rodriguez-Gonzalez M (2022) Left ventricular hypertrophy in patients with X-linked hypophosphataemia. J Clin Res Pediatr Endocrinol 14:344\u2013349. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2021.2020.0287","journal-title":"J Clin Res Pediatr Endocrinol"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01169-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-023-01169-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01169-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T13:03:57Z","timestamp":1709125437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-023-01169-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1007\/s00223-023-01169-x","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"13 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KB: fees for conference organization, board member of the XLH registry sponsored by KYOWA KIRIN PHARMA and participation in burosumab clinical trials conducted by KYOWA KIRIN PHARMA. GM: fees for moderating a round table during a conference organized by KYOWA KIRIN PHARMA. AMC, EB, DP, JN, and MC have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient has been informed and has not objected to the use of this data for this publication, which has been collected in compliance with the requirements of the CNIL (Commission Nationale de l'Informatique et des Libert\u00e9s). Under these conditions, recourse to an ethics commission is optional under French legislation. Signed consent to participate in research was obtained from our Physiology Department.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}